Shares shifted as Trulieve Cannabis (TRLV) slid 3.1% to $8.72 after posting second-quarter results that revealed a company in the middle of a radical metamorphosis. Revenue of $271 million missed Wall Street's estimate of roughly $274 million , and the company reported a net loss of $406 million, or $2.10 per share, which included a $407 million impact from the Harvest deconsolidation . The headline numbers obscure a deeper strategic gamble: Trulieve voluntarily shrunk itself to gain a bigger stage.
The Revenue Miss Is Small, but the Business Is Structurally Smaller Now
Q2 results included Harvest operations only through June 3, when deconsolidation took effect, meaning most of the quarter reflected medical-only revenue . Stripping out Harvest, medical-only revenue was $222 million, and revenue fell 10% year-over-year . Management guided Q3 revenue to roughly $222 million — flat with the medical-only base — signaling that the top line has effectively reset lower. Investors accustomed to a $300 million quarterly run rate must now price a meaningfully smaller company.
A $406 Million Loss That's Mostly on Paper
The deconsolidation triggered a $403 million non-cash charge , inflating the GAAP loss. Adjusted net income was $20 million, or $0.11 per share , beating estimates of $0.06. The company generated $53 million in operating cash flow and $32 million in free cash flow during the quarter . The underlying business is profitable — but the accounting noise makes it hard for new NYSE-listed institutional buyers to parse quickly.
The NYSE Listing Came at a Price — and the Forward Outlook Got Trimmed
Trulieve shed Harvest's mixed-use cannabis states — Arizona, Connecticut, Maryland, and Ohio — selling a 10% voting stake for $14.8 million to an outside investor and restructuring governance to remove control . That trade-off unlocked the NYSE ticker but also forced management to cut guidance: full-year operating cash flow was lowered to at least $225 million (from $250 million), while capital spending was raised to $95 million . The math implies less cash left over for shareholders, even as Trulieve announced a $50 million buyback program .
Georgia and Texas Are the Growth Story — but They're Still Early
Trulieve ended Q2 with $325 million in cash, 207 dispensaries, and expansion underway in Georgia and Texas . Management expects growth to accelerate into year-end as those states ramp . Whether two nascent medical markets can replace the revenue and profit lost from four adult-use states is the question that will determine if $8.72 is a floor or a waypoint lower.